Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 11.50p 11.00p 12.00p 11.50p 11.50p 11.50p 42,099 06:33:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.4 -3.1 - 10.51

Synairgen Share Discussion Threads

Showing 651 to 673 of 675 messages
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
DateSubjectAuthorDiscuss
08/11/2017
21:47
Richard Griffiths has further increased his stake in SNG 16:31 Today ...SNG RNS details Richard Griffiths has further increased his stake in SNG from 13.95% to 14.68%.. (13,416,112 shares he now owns) His faith in SNG delivering is being matched by his pocket.
rosejs2
08/11/2017
07:19
Great, thanks for the information.
pdt
08/11/2017
05:04
Hi - TD Waterhouse UK now taken over by iii will let you do that hxxps://www.tddirectinvesting.co.uk/share-dealing
ohisay
07/11/2017
20:23
ohisay - have had a look at PXS but cannot hold in either my ISA or SIPP. Do you know how they can be purchased in the UK?
pdt
07/11/2017
15:19
Well spotted sir .SNG IS a 12 month stock but its exceptionally cheap if either of its lead drugs come off .Have you considered PXS the OZ partner ? - huge chunk of its market cap is in cash.
ohisay
07/11/2017
13:09
I saw an article about a 15 minute GP test to determine if the problem was viral or bacterial; hTTp://www.dailymail.co.uk/health/article-5052565/The-15-minute-test-tells-GP-need-antibiotics.html Would certainly help with the COPD study to ensure just viral cases are treated. I think the company was talking about a 1 hour test? I wonder if it's the same test. I have just bought a few here. 2018 looks like it could be an interesting year. Happy to have a 12 to 18 month time horizon to see how it goes. Other holdings are IMM and EVG. The former has paid off but still waiting on EVG, very much a game of patience with pharma stocks.
pdt
02/11/2017
07:31
I'll be there tonight ohisay I suspect most attendees will be focused on Immupharma, given where they are on their lead compound (I hold a few). My main questions for RM will be around funding. I'm guessing they will probably need to raise a small amount to get them through the proposed COPD study, the question is how much and by what means and if it's via an equity raise, will the shares qualify for EIS tax breaks?
timbo003
01/11/2017
04:10
[...] Proactive Investors One2One Investor Forum - London ImmuPharma PLC | Synairgen plc | WideCells Group Nov 2nd 2017, 6.00 pm - Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair Wish I could be there but at least Timbo here (hopefully) will be reporting back.
ohisay
27/10/2017
05:38
Mentioned in PXS quartely report today. LOXL2 inhibitor program set to commence phase 1 clinical trials In September Pharmaxis and its collaborator UK biotechnology company Synairgen plc (AIM: SNG) announced completion of the preclinical development stage of their anti‐fibrotic Lysyl Oxidase type 2 (LOXL2) inhibitor program allowing the program to commence human clinical phase I studies in Q4 2017. The Pharmaxis drug discovery group has developed a number of selective small molecule inhibitors to the LOXL2 enzyme utilising the same amine oxidase platform that delivered BI‐ 1467335. The LOXL2 enzyme is fundamental to the fibrotic cascade that follows chronic inflammation in the liver disease NASH, cardiac fibrosis, kidney fibrosis, and idiopathic pulmonary fibrosis (IPF), and it also plays a role in some cancers. An extensive pre‐clinical program performed on the program compounds confirmed they have all the characteristics of a successful once a day, oral drug, showing excellent efficacy in several different in vivo fibrosis models including fibrosis of the liver, lung, kidney and heart. In regulatory toxicity studies, the compounds have been well tolerated and shown a good safety profile. Partnering plan for LOXL2 program Pharmaxis has been discussing its LOXL2 program with large pharma companies since the beginning of 2016. There is interest in the program as it is one of the very few truly anti‐fibrotic mechanisms in clinical development. In parallel with the commencement of phase 1 clinical trials, Pharmaxis will enable scientific due diligence of the program by select large pharma companies interested in subsequent partnering discussions.
ohisay
23/10/2017
05:00
http://www.dailystar.co.uk/news/latest-news/654359/aussie-flu-h3n2-h2n2-jab-britain-warning-disease-epidemic Just the kind of environment a COPD sufferer would do really badly in. If the flu season here is as bad as forecast I find it inconceivable that SNG wont get very good results from its SNG001 winter trial on a COPD group population.
ohisay
20/10/2017
16:07
Nioe see some interest today but still blitheringly cheap IMV . I'm half expecting them to have some non dilutive funding sorted out before they present on 2/11.
ohisay
19/10/2017
02:05
https://www.youtube.com/watch?v=fNOvqLAILxs Pharmaxis released a few new videos including references to the collaboration with SNG on LOXL. Encouraging that the CEO seems to be quite well connected. hxxp://www.biotech-capital.com/companies/news/185843/pharmaxis-boosts-its-drug-discovery-ranks-185843.html
ohisay
18/10/2017
13:26
Synairgen CEO Richard Marsden will be presenting to investors at the upcoming Proactive One2One Healthcare Forum taking place on 2nd November in Mayfair, London. Full details here: https://tinyurl.com/yab536cw
aim_trader
12/10/2017
09:07
Shoukd be no shortage of patients this winter for that "flu exacerbation trial" for SNG001. http://www.itv.com/news/2017-10-12/major-flu-outbreak-could-overwhelm-the-nhs-this-winter-and-suspend-routine-operations-for-months/ A heavy outbreak of flu in the Southern Hemisphere during winter there prompted NHS England boss Simon Stevens to warn hospitals to be prepared for a "pressurised" flu season. Mr Stevens said the health service was reviewing the situation in Australia and New Zealand, where hospitals were forced to close their doors to new patients and people faced long waiting times. But Dr Scriven said that despite talk of preparations, doctors on the frontline feel as though there is "nothing new other than crossed fingers". "Over the last two to three years we haven't had to deal with any major outbreaks of infection such as norovirus or flu, but this year we are predicting a bad flu season that will overwhelm us after what we've witnessed in Australia and New Zealand," he said.
ohisay
04/10/2017
04:12
thanks for picking that up Timbo - as you say he seems quite energised.
ohisay
29/9/2017
20:25
RM sounds quite upbeat in today's Proactive interview: https://www.youtube.com/watch?v=yTruRiXVs-A Also I see that Synairgen are down to attend the Proactive meeting on November 2nd, so I've booked my place: http://www.proactiveinvestors.co.uk/register/event_details/119
timbo003
27/9/2017
13:31
Lol I've been here since 2011 - its always been one of my largest holdings - I've just managed to trade as well too - adding on xtremely oversold levels. Griffiths has added about 10% over the last 30 months too as i recall - I think its possible he could add here after today too - its been derisked now much much more than the market currently thinks. Look at it this way the market has only added 7m$ to the market cap for derisking both LOXL and SNG001. I'd say this is as attractive an entry point as I 've seen in the last 7 years but dyor - Im fully loaded.
ohisay
27/9/2017
12:12
ohisay.. you are not the only fans of this share...A recap of the major shareholders may help... Name of shareholder Number of ordinary shares % of share capital Woodford Investment Management 21,091,651 23.1% Lansdowne Partners 16,923,111 18.5% Richard Griffiths 12,741,112 13.9% Southampton Asset Management Limited 3,600,000 3.9% Leonard Licht 3,700,000 4.1% With 100% ownership of SNG001, offering a financial share in SNG001 to the right partner to fund the proposed Phase 2B trial would also I believe be a game changer..and limit any major dilution of share capital.. With the LOXL2 Programme looking very positive ... This share will soon be moving substantially onwards and importantly upwards... Be patient .. The rewards could be substantial..
rosejs2
27/9/2017
11:10
[...] Richard Marsden, Synairgen’s chief executive, said: "We have long been conscious that COPD is the key target market for a broad spectrum antiviral such as SNG001. Until recently, the difficulties of patient selection and the associated cost of the required trials made it prohibitively expensive to pursue. The fact that high viral exacerbation rates are now evident, combined with the launch of an effective diagnostic for viral infections, means that a COPD programme is now both highly attractive and economically viable. "Finally, our new analysis of the INEXAS trial data suggests a complementary result to our previous trial indicating that we can improve important clinical endpoints in the lungs, which increases our confidence as we move into the significant opportunity that is COPD."
ohisay
27/9/2017
10:57
We appear to be the only fans of this stock Timbo ! so while I share your thoughts about the header it isnt as if a change of title is going to make much difference to investors it seems .. I bought these all the way down to 7p and bought more today - that announcement tells me they have other irons in the fire other than share dilution to pay for their two trials - they have 100% back of SNG001 and could easily farm out a good chunk of that for some small cash infusion I'd have thought. Just hugely undervalued now with an ev of just 11m$ for two decent drug candidates. Be interested to see Finn caps take now - my short term target is 14p .
ohisay
27/9/2017
07:45
The proposed COPD proof of concept study with interferon makes a lot of sense, dont know how they will pay for it though, but note the wording in this mornings statement:. We are excited about progressing the development of SNG001 into COPD, with a Phase II trial in targeted "at risk" patients in the final stages of preparation. In parallel, we are considering optimal financing strategies to enable us to progress this exciting development over the medium term. On a related topic, I think we desperately need a new thread, I have never liked the title on this one and now it is even more irrelevant and misleading.
timbo003
08/9/2017
00:43
https://www.youtube.com/watch?v=6uIXJ22ESb4 Pharmaxis on LOXL - well worth watching
ohisay
07/9/2017
15:54
15p tomorrow??
miahkaysor
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20171120 17:32:59